Shots:
- The US FDA has approved Padcev (enfortumab vedotin) + Keytruda/Keytruda Qlex for neoadj. & adj. treatment for pts with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility
- Approval was supported by the P-III (EV-304/KEYNOTE-B15) trial assessing neoadj. Padcev + Keytruda, followed by surgery & then adj. Keytruda + Padcev vs neoadj. SoC + surgery in cisplatin-eligible MIBC pts (n=808)
- Trial showed a 47% reduction in the risk of EFS events (mEFS: not reached vs 48.5mos.), & a 35% decrease in death risk (mOS was not reached for either arm). It also showed a pCR rate of 55.8% vs 32.5%
Ref: Businesswire | Image: Merck, Pfizer & Astellas | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
